Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745643 | 1.00 | KDM4E (0.32) | KDM4EALDH1A1LMNAMAPTGPR84 | |
| SCHEMBL20972701 | 1.00 | KDM4E (0.32) | KDM4EALDH1A1LMNAMAPTGPR84 | |
| SCHEMBL20972699 | 0.82 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL20972563 | 0.82 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL20745519 | 0.82 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL20745753 | 0.80 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL20745752 | 0.80 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL20745262 | 0.76 | KDM4E (0.30) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL20972591 | 0.74 | GPR84 (0.39) | KDM4EALDH1A1LMNAMAPTGPR84 | |
| SCHEMBL20745498 | 0.74 | GPR84 (0.39) | KDM4EALDH1A1LMNAMAPTGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3988555-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-111818917-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2020-10-23 | — | — | CN | disclosed |
| US-20200325153-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2020-10-15 | — | — | US | disclosed |
| US-10676485-B2 | Macrocyclic MCL-1 inhibitors and methods of use | ABBVIE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190144465-A1 | Macrocyclic MCL-1 inhibitors and methods of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676485-B2 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | KDM4E 1725/4885ALDH1A1 641/4885LMNA 420/4885 |
| US-20190144465-A1 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | KDM4E 1519/4885ALDH1A1 724/4885LMNA 495/4885 |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | MCL1, BCL2A1, BCL2L10 | KDM4E 1725/4885ALDH1A1 641/4885LMNA 420/4885 |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | KDM4E 1725/4885ALDH1A1 641/4885LMNA 420/4885 |
| US-20200325153-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | MCL1, BCL2A1, BCL2L10 | KDM4E 1725/4885ALDH1A1 641/4885LMNA 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.